What's in LI ZHAO's pipeline?

LI ZHAO has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with LI ZHAO's portfolio?

Top competitors by shared drug class: M.D. Anderson Cancer Center, Nara Medical University, Scios, Inc., VA Office of Research and Development.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/li-zhao.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

LI ZHAO — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LI ZHAO pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
rhBNP	rhBNP	marketed	Natriuretic peptide	Natriuretic peptide receptor-A (NPR-A)	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

M.D. Anderson Cancer Center · 1 shared drug class
Nara Medical University · 1 shared drug class
Scios, Inc. · 1 shared drug class
VA Office of Research and Development · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for LI ZHAO:

Cite this brief

Drug Landscape (2026). LI ZHAO — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/li-zhao. Accessed 2026-06-10.